Business

Powered by
 
Canadian-Related Releases

NPS Pharmaceuticals to Present at Oppenheimer Healthcare Conference

Oppenheimer Healthcare Conference 2013

BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Oppenheimer 24th Annual Healthcare Conference in New York on Tuesday, December 10, 2013 at 9:10 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors’ calendar of events page on the NPS website at http://www.npsp.com/calendar.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (U.S.)/Revestive® (EU) (teduglutide [rDNA origin]) for injection is approved for adult Short Bowel Syndrome (SBS) patients who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism and submitted its marketing application to the U.S. Food and Drug Administration in October 2013. NPS's earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin.

Contacts

NPS Pharmaceuticals, Inc.
Gail Brophy, (908) 450-5335

Company Information Center

NPS Pharmaceuticals, Inc. RSS feed for NPS Pharmaceuticals, Inc.

NASDAQ:NPSP

ISIN: US62936P1030